NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., filing under ticker BRPA, submitted an 8-K to the Securities and Exchange Commission on October 11, 2024, accession number 0001437749-24-031133. The company is the post-combination entity resulting from a merger with Big Rock Partners Acquisition Corp, a blank-check vehicle sponsored by Big Rock Partners that completed its initial public offering in 2018. Operating in the biopharmaceutical sector, NRX Pharmaceuticals is focused on treatments for central nervous system disorders and critical care indications. The October 2024 filing reflects continued corporate disclosure obligations for the combined company under its healthcare mandate. For full filing history, sponsor profiles, and deal analytics on BRPA and hundreds of other SPACs, sign up for complete data access at SpacDesk.